FDA places hold on MacroGenics’ bispecific antibody trials over liver toxicity concerns

FDA places hold on MacroGenics’ bispecific antibody trials over liver toxicity concerns

Two trials involving the drug MGD009 – a monotherapy study and one in combination with the company’s PD-1 inhibitor – are barred from enrolling new patients pending FDA review and a planned protocol amendment.

Source: https://ift.tt/2Eknw7q